


# TARGETING APOPTOSIS FAD ASINCRONA

START



**01/06/2023**

STOP



**31/12/2023**

**EVENTO ECM - FAD ASINCRONA | PIATTAFORMA [WWW.PROEVENTIFAD.IT](http://WWW.PROEVENTIFAD.IT)**

Responsabile Scientifico :  
Giovanni Martinelli - Direttore Scientifico IRCCS IRST Meldola "Dino Amadori"

## PROGRAMMA SCIENTIFICO

**TARGETING APOPTOSIS PATHWAYS IN MUTATED LEUKEMIA (20 MIN)**  
GIORGIA SIMONETTI, IRST, MELDOLA, ITALY



**TARGETING PYROPTOSIS PATHWAYS IN CANCER AND LEUKEMIA (20 MIN)**  
DOMENICO GIRELLI, UNIVERSITY OF VERONA, VERONA, ITALY



**TARGETING DISSULFIDE STRESS-INDUCED APOPTOSIS (20 MIN)**  
GIOVANNI MARCONI, IRST, MELDOLA, ITALY



**BCL2 INHIBITORS: VENETOCLAX AND AZACYTIDINE AS A MODEL (20 MIN)**  
MICHAEL ANDREEF, MD ANDERSON CANCER CENTER, HOUSTON, TX



**BCL2 INHIBITORS: VENETOCLAX AND DECITABINE AS A MODEL (20 MIN)**  
COURTNEY DINARDO, MD ANDERSON CANCER CENTER, HOUSTON, TX



**OPTIMIZING THE USE OF BCL2 INHIBITORS: THE AVALON EXPERIENCE (20 MIN)**  
GIOVANNI MARCONI, IRST, MELDOLA, ITALY



**BCL2 INHIBITORS IN CLL: HOW WE LEARN? (20 MIN)**  
CLAUDIO CERCHIONE, IRST, MELDOLA, ITALY



**BCL2/BCLX INHIBITORS: THE NAVITOCCLAX HISTORY (20 MIN)**  
CRISTINA PAPAYANNIDIS, ISTITUTO SERAGNOLI, BOLOGNA, ITALY



**THE BCL2/BCLX INHIBITOR NAVITOCCLAX IN T-ALL EXPERIENCE (20 MIN)**  
ELIAS JABBOUR, MD ANDERSON CANCER CENTER, HOUSTON, TX



Evento FAD ASINCRONA  
n.383332-2773 (Obiettivo n.3)

**N. 5 CREDITI ECM per**

**MEDICI, INFERMIERI, FARMACISTI, BIOLOGI, TSLB**

Quiz apprendimento al termine della visione delle 9 registrazioni.

**Iscrizione e partecipazione gratuita [www.proeventifad.it](http://www.proeventifad.it)**

Inizio evento 01/06/2023 - termine evento 31/12/2023

PROVIDER N. 2773



INFO@PROEVENTI.IT  
WWW.PROEVENTI.IT

CON IL CONTRIBUTO EDUCAZIONALE NON CONDIZIONANTE DI

**abbvie werfen**